Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD) in South Africa

Total 2790 results

Nuvaira, Inc.

Completed

Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (IPS-I)

Chronic Obstructive Pulmonary Disease (COPD)

Netherlands, South Africa
AstraZeneca

Completed

The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)

Chronic Obstructive Pulmonary Disease, COPD

France, Poland, South Africa, Spain, United States, Canada, United Kingdom
Novartis

Completed

A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Spain, Germany, South Africa, Australia, Poland, New Zealand, Netherlands
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)

Chronic Obstructive Pulmonary Disease | COPD

Austria, France, Hungary, Italy, Poland, Portugal, Russian Federation, South Africa, Spain, Canada, United Kingdom, Australia, Netherlands, Switzerland
Mylan Inc.
Theravance Biopharma

Completed

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom, South Africa
AstraZeneca

Completed

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Nephron Pharmaceuticals Corporation
Rho, Inc.

Completed

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Chronic Obstructive Pulmonary Disease COPD

United States, Netherlands, Argentina, South Africa, Chile, Peru
Macquarie University, Australia

Completed

The Use of Aeriseal ® in the Management of Collateral Ventilation Positive COPD Patients Undergoing ELVR Utilizing Endobronchial Valves.

Chronic Obstructive Pulmonary Disease (COPD)

Australia
Sunovion

Completed

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Dey

Completed

A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

Chronic Obstructive Pulmonary Disease | COPD

United States, France, Poland, South Africa, Canada, Germany
AstraZeneca
Quintiles, Inc.

Completed

Adherence Study in COPD Patients

Chronic Obstructive Pulmonary Disease (COPD

United States
Sunovion

Completed

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
AstraZeneca

Completed

Phase IV O2 Consumption Study in COPD Patients.

Chronic Obstructive Pulmonary Disease (COPD)

United States
Mylan Inc.
Theravance Biopharma

Completed

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
Novartis Pharmaceuticals

Completed

Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

Spain, Germany, Belgium, Poland, South Africa, Australia, Greece, Israel, Sweden, Hong Kong, Thailand, Bulgaria, Singapore, Denmark, Finland, Hungary, Romania, Malaysia
Elpen Pharmaceutical Co. Inc.

Recruiting

Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice. (ARGO)

Copd | COPD Exacerbation

Greece
Alkermes, Inc.

Completed

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST1)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Argentina, Germany, Spain, Turkey, Guatemala, Mexico, Australia, Denmark, South Africa, Philippines
Novartis

Completed

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Spain, Turkey, France, Netherlands, Germany
Mylan Inc.
Theravance Biopharma

Completed

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

Chronic Obstructive Pulmonary Disease, COPD | Low Peak Inspiratory Flow Rate (PIFR)

United States
Guy's and St Thomas' NHS Foundation Trust
King's College London; University of Nottingham; Imperial College London; University... and other collaborators

Not yet recruiting

Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease (RAPID)

COPD | COPD Exacerbation

United Kingdom
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, United States, Canada, India, Italy, Poland, South Africa
AstraZeneca

Completed

Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127) (EOS)

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Belgium, Canada, France, Germany, Italy, Netherlands, South Africa, Spain, United Kingdom
AstraZeneca
Parexel

Completed

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

Chronic Obstructive Pulmonary Disease - COPD

United States
Novartis Pharmaceuticals

Completed

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Chronic Obstructive Pulmonary Disease, COPD

Poland, United States
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
AstraZeneca

Completed

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)

Chronic Obstructive Pulmonary Disease (COPD)

France, Germany, United Kingdom, United States, Australia, Austria, Brazil, Hungary, New Zealand, Romania, Russian Federation
AstraZeneca

Completed

Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, South Africa, Spain, United Kingdom
Sunovion

Completed

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
GlaxoSmithKline

Completed

Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.

Asthma

Australia, New Zealand
AstraZeneca

Recruiting

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (CRESCENDO)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Denmark, Germany, South Africa, Spain, United Kingdom, Italy, Argentina, Bulgaria, Mexico, Turkey, Poland, Netherlands
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
Sunovion

Terminated

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Chronic Obstructive Pulmonary Disease (COPD)

United States
Glenmark Specialty S.A.

Completed

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

United States
Chiesi Farmaceutici S.p.A.

Completed

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (GLIMMER)

Chronic Obstructive Pulmonary Disease | COPD

United States
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
AstraZeneca
Parexel International Ltd; Cognizant Technology Solution; Center for Information... and other collaborators

Completed

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO)

Chronic Obstructive Pulmonary Disease COPD

United States, Canada, France, Russian Federation, Ukraine, Hungary, Bulgaria
AstraZeneca

Completed

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. (ASCENT COPD)

Chronic Obstructive Pulmonary Disease | COPD | Moderate to Very Severe COPD

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease (INTRUST2)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Spain, Canada, Slovakia, India, Netherlands, Czech Republic, Hungary
AstraZeneca

Completed

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® (SPEED)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil, United Kingdom, Germany, Philippines, Denmark, Australia, Argentina, India, Belgium
AstraZeneca

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis (FRONTIER-4)

Chronic Obstructive Pulmonary Disease (COPD) | Chronic Bronchitis

United States, Canada, Denmark, Spain, United Kingdom, Taiwan, New Zealand, Australia, Germany, Israel, South Africa, Czechia, Hungary, Poland, Netherlands
AstraZeneca

Completed

Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom

Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD) in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations